权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Immunomodulatory Therapy of Multiple Myeloma with SMAC Mimetics

使用 SMAC 模拟物对多发性骨髓瘤进行免疫调节治疗

基本信息

批准号：
9152284
负责人：
Marta Chesi
金额：
$ 26.33万
依托单位：
MAYO CLINIC ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9152284
关键词：
Agonist Anemia Apoptosis Apoptosis Inhibitor Bone Marrow Bone Marrow Cells Bortezomib CCL2 gene CD47 gene CSF1R gene Cell Line Cell Transplantation Cells Chemotactic Factors Clinic Clinical Clinical Trials Coculture Techniques Cyclophosphamide Dexamethasone Dichloromethylene Diphosphonate Disease Dose-Limiting Enrollment Evaluation Genetic Heterogeneity Genetically Engineered Mouse Genomic Instability Goals Growth Heterogeneity Human IL8 gene Immune Immune response Immune system Immunomodulators Immunosuppression Immunosuppressive Agents In Vitro Interleukin-12 Liposomes Malignant Neoplasms Mediating Mediator of activation protein Modeling Molecular Molecular Profiling Molecular Target Multiple Myeloma Mus Oxides Pathway interactions Patients Phase II Clinical Trials Plasma Plasma Cells Pre-Clinical Model Reporting Role Sampling Serum Signal Transduction Solid Neoplasm Syndrome TNFRSF5 gene Therapeutic Toll-like receptors Transplantation Xenograft Model Xenograft procedure adaptive immunity angiogenesis antitumor effect bone cIAP1 protein cellular targeting chemotherapy clinically relevant cytokine in vivo inhibitor-of-apoptosis protein macrophage mimetics monocyte mouse model neoplastic cell novel phase I trial research study synergism targeted treatment tumor tumorigenic

项目摘要

PROJECT SUMMARY—ABSTRACT Multiple myeloma (MM) is a genetically heterogeneous disease, with varying levels of genomic instability and intra-tumor clonal heterogeneity. Both levels of heterogeneity pose challenges for directed anti-tumor targeted therapy, which may be overcome by harnessing the power of the immune system. LCL161 is a SMAC mimetic targeting the cellular inhibitor of apoptosis proteins cIAP1 and -2 (cIAP1/2). We previously reported that bi- allelic deletions of cIAP1/2 in MM result in activation of the non canonical NFkB pathway, and consistently LCL161 has little direct anti-tumor activity, against primary MM cells, MM cell lines, or xenograft models where it induces even higher levels of NFkB. However, LCL161 has dramatic activity in vivo against MM that develops spontaneously in the immuno-competent and clinically predictive Vk*MYC mouse model, but not in vitro against these same tumor cells, suggesting an important role for the host in mediating the anti-tumor effect. Transplantation and cell depletion experiments in Vk*MYC mice implicated macrophages as mediator of LCL161 anti-MM activity that does not depend on adaptive immunity. MΦ are a crucial component of the MM niche and support MM growth by providing survival signals and promoting immunosuppression. However macrophages can be re-educated to acquire tumoricidal activity by CSF1R inhibition, anti-CD47 treatment or combinations of Toll-like-receptor (TLR) agonists + IFNg, TLRa + CD40 agonist or chemotherapy. We found that the SMAC mimetic compound (SMC) LCL161 also promotes macrophages M1 polarization and potent anti-MM activity in vivo. Specifically, LCL161 treatment induced M1 polarization and tumoricidal activity in BM derived macrophages co-cultures experiments, and induction of M1 cytokines in plasma from MM patients enrolled in the clinical trial. The goal of this proposal is to define the mechanisms implicated in LCL161 anti-MM activity in Vk*MYC mice and in samples obtained from MM patients enrolled in a phase II clinical trial of LCL161 at the Mayo Clinic.

项目SUMMARY-ABSTRACT